Sažetak
Background: Sintilimab, a PD-1 inhibitor, has emerged as a promising immunotherapeutic agent in gastric cancer. However, its impact on laboratory-based biochemical markers and immune indicators remains underexplored. This meta-analysis aimed to evaluate the changes in tumor biomarkers and T lymphocyte subsets, alongside clinical outcomes, in patients receiving sintilimab.
Methods: A comprehensive literature search of randomized controlled trials (2022–2025) was conducted across CNKI, Wanfang, VIP, and PubMed databases. Primary outcomes included serum tumor markers (CEA, CA199, CA242) and immune parameters (CD4⁺, CD8⁺ T-cell subsets). Secondary outcomes were ORR, DCR, OS, PFS, and adverse reactions. RevMan 5.2 was used for meta-analysis.
Results: Sixteen studies were included. Sintilimab treatment significantly reduced CEA, CA199, and CA242 levels (P < 0.0001), and favorably modulated immune subsets by increasing CD4⁺ and decreasing CD8⁺ cell counts. These biochemical and immunological improvements correlated with higher ORR, DCR, and OS, without increased adverse events (P > 0.05).
Conclusion: Sintilimab confers measurable improvements in key laboratory-based tumor and immune biomarkers, supporting its utility in clinical biochemical monitoring and immunotherapy response evaluation for gastric cancer patients. These findings align with the emerging integration of immunotherapy and biochemical diagnostics in oncology.
Ključne reči
Array
Array
Array
Array
Array
Array
Array
Array
Array
Reference
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.